The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Mounjaro shortage update: Is it on backorder and when will it be back in stock? Mounjaro and Zepbound manufacturer Eli Lilly has battled supply issues since weight loss injectables took off.

Zepbound has been a major hit, ... Now, it’s worth noting Stock Advisor ’s total average return is 998 % — a market-crushing outperformance compared to 174 % for the S&P 500.

Here's 1 Stock to Buy Hand Over Fist in 2024, ... But when thinking about the long term, investors should consider that Eli Lilly has yet to really benefit from Zepbound.

Lilly’s stock has gone up by 590% in the past five years, mainly due to its successful new drug launches, particularly Mounjaro and Zepbound, and its solid pipeline potential.